Resolvyx Pharmaceuticals is developing a new class of lipid mediators, dubbed resolvins, which are generated through the oxidation of the omega-3 fatty acids EPA and DHA. Although omega-3 fatty acids have long been heralded for their reputed ability to reduce inflammation, many grams of omega-3 fatty acids have to be consumed to produce any physiological effect. In contrast, Resolvyx says its resolvins are potent at low milligram quantities and so are good candidates for commercialization as drugs. Resolvyx is advancing two programs into the clinic.
Resolving inflammation, broadly
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.
Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.
